US Patent Issued to Janssen Pharmaceutica on April 15 for "Method of determining Acute Myeloid Leukemia response to treatment with farnesyltransferase inhibitors" (New Jersey, California Inventors)

ALEXANDRIA, Va., June 5 -- United States Patent no. 12,274,711, issued on April 15, was assigned to Janssen Pharmaceutica NV (Beerse, Belgium).

"Method of determining Acute Myeloid Leukemia response to treatment with farnesyltransferase inhibitors" was invented by Tatiana I. Vener (Stirling, N.J.), Carlo C. Derecho (Lakehurst, N.J.), John F. Palma (Alamo, Calif.) and Mical Raponi (San Francisco).

According to the abstract* released by the U.S. Patent & Trademark Office: "The disclosed method rapidly identifies with desired accuracy AML patients, including elderly AML patients, likely to respond to treatment with a combination of a farnesyltransferase inhibitor and one or more of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, tem...